FI3166615T3 - Kelatoituja fosforotioaattinukleiinihappopolymeerejä käytettäväksi yhdistelmänä HBV-polymeraasin inhibiittorin kanssa hepatiitti B- ja hepatiitti D -virusinfektioiden hoitamiseksi - Google Patents
Kelatoituja fosforotioaattinukleiinihappopolymeerejä käytettäväksi yhdistelmänä HBV-polymeraasin inhibiittorin kanssa hepatiitti B- ja hepatiitti D -virusinfektioiden hoitamiseksi Download PDFInfo
- Publication number
- FI3166615T3 FI3166615T3 FIEP15818148.7T FI15818148T FI3166615T3 FI 3166615 T3 FI3166615 T3 FI 3166615T3 FI 15818148 T FI15818148 T FI 15818148T FI 3166615 T3 FI3166615 T3 FI 3166615T3
- Authority
- FI
- Finland
- Prior art keywords
- composition
- pharmaceutically acceptable
- nucleic acid
- hbv
- use according
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims 16
- 108020004707 nucleic acids Proteins 0.000 title claims 14
- 102000039446 nucleic acids Human genes 0.000 title claims 14
- 150000007523 nucleic acids Chemical class 0.000 title claims 11
- 108700024845 Hepatitis B virus P Proteins 0.000 title claims 6
- 229940123066 Polymerase inhibitor Drugs 0.000 title 1
- 208000002672 hepatitis B Diseases 0.000 title 1
- 208000029570 hepatitis D virus infection Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 29
- 125000003729 nucleotide group Chemical group 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 108091034117 Oligonucleotide Proteins 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 8
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 8
- 150000004697 chelate complex Chemical class 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- 208000003322 Coinfection Diseases 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 230000004048 modification Effects 0.000 claims 5
- 239000002777 nucleoside Substances 0.000 claims 5
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 5
- -1 phosphorothioate nucleic acid Chemical class 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 238000009169 immunotherapy Methods 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 150000003291 riboses Chemical class 0.000 claims 3
- PULHSZUYKJKPMM-WDSKDSINSA-M (2s)-2-[(2s)-2-amino-3-methylbutanoyl]oxypropanoate Chemical compound CC(C)[C@H](N)C(=O)O[C@@H](C)C([O-])=O PULHSZUYKJKPMM-WDSKDSINSA-M 0.000 claims 2
- RTJUXLYUUDBAJN-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](F)[C@@H](CO)O1 RTJUXLYUUDBAJN-KVQBGUIXSA-N 0.000 claims 2
- JXQUAHHUSMJUFV-HZPZRMRQSA-N 9-[2-[[(2r,4s)-4-(3-chlorophenyl)-2-oxo-1,3,2$l^{5}-dioxaphosphinan-2-yl]methoxy]ethyl]purin-6-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1([C@@H]2CCO[P@](O2)(=O)COCCN2C=3N=CN=C(C=3N=C2)N)=CC=CC(Cl)=C1 JXQUAHHUSMJUFV-HZPZRMRQSA-N 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 2
- KDNSSKPZBDNJDF-UHFFFAOYSA-N [1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethylphosphonic acid Chemical compound C12=NC(N)=NC=C2N=CN1CC1(OCP(O)(O)=O)CC1 KDNSSKPZBDNJDF-UHFFFAOYSA-N 0.000 claims 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 2
- 229960003205 adefovir dipivoxil Drugs 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 229950002782 besifovir Drugs 0.000 claims 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 2
- 229960005338 clevudine Drugs 0.000 claims 2
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 claims 2
- 229960000366 emtricitabine Drugs 0.000 claims 2
- 229960000980 entecavir Drugs 0.000 claims 2
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000010253 intravenous injection Methods 0.000 claims 2
- 229950003808 lagociclovir Drugs 0.000 claims 2
- 229960001627 lamivudine Drugs 0.000 claims 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- 229960005311 telbivudine Drugs 0.000 claims 2
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims 2
- 229960003560 tenofovir alafenamide fumarate Drugs 0.000 claims 2
- SVUJNSGGPUCLQZ-FQQAACOVSA-N tenofovir alafenamide fumarate Chemical compound OC(=O)\C=C\C(O)=O.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 SVUJNSGGPUCLQZ-FQQAACOVSA-N 0.000 claims 2
- STGXGJRRAJKJRG-JDJSBBGDSA-N (3r,4r,5r)-5-(hydroxymethyl)-3-methoxyoxolane-2,4-diol Chemical compound CO[C@H]1C(O)O[C@H](CO)[C@H]1O STGXGJRRAJKJRG-JDJSBBGDSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- HSBKFSPNDWWPSL-VDTYLAMSSA-N 4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1C=C[C@H](CO)O1 HSBKFSPNDWWPSL-VDTYLAMSSA-N 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229950006528 elvucitabine Drugs 0.000 claims 1
- 229960001355 tenofovir disoproxil Drugs 0.000 claims 1
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 claims 1
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462022846P | 2014-07-10 | 2014-07-10 | |
| US201462091943P | 2014-12-15 | 2014-12-15 | |
| PCT/CA2015/050626 WO2016004525A1 (en) | 2014-07-10 | 2015-07-07 | Methods for the treatment of hepatitis b and hepatitis d virus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3166615T3 true FI3166615T3 (fi) | 2023-11-06 |
Family
ID=55063440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP15818148.7T FI3166615T3 (fi) | 2014-07-10 | 2015-07-07 | Kelatoituja fosforotioaattinukleiinihappopolymeerejä käytettäväksi yhdistelmänä HBV-polymeraasin inhibiittorin kanssa hepatiitti B- ja hepatiitti D -virusinfektioiden hoitamiseksi |
Country Status (33)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11166976B2 (en) * | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| WO2020097342A1 (en) * | 2018-11-08 | 2020-05-14 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| US20210189392A1 (en) * | 2019-12-12 | 2021-06-24 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| CN113620993A (zh) * | 2020-05-07 | 2021-11-09 | 西安新通药物研究股份有限公司 | 甲磺酸帕拉德福韦d晶型及其应用 |
| WO2021223398A1 (zh) * | 2020-05-07 | 2021-11-11 | 西安新通药物研究股份有限公司 | 治疗肝病的晶型及其应用 |
| CN114057816B (zh) * | 2020-07-30 | 2025-02-11 | 浙江柏拉阿图医药科技有限公司 | 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用 |
| US20220160748A1 (en) * | 2020-11-20 | 2022-05-26 | Aligos Therapeutics, Inc. | Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting |
| WO2022133230A1 (en) | 2020-12-18 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| WO2022152869A1 (en) | 2021-01-15 | 2022-07-21 | Janssen Sciences Ireland Unlimited Company | Use of oligonucleotides for individuals with hepatic impairment |
| WO2022261046A1 (en) * | 2021-06-07 | 2022-12-15 | Antios Therapeutics, Inc. | Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs |
| JP2024527380A (ja) | 2021-07-09 | 2024-07-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド | 腎機能障害を有する個体へのオリゴヌクレオチドの使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5482836A (en) * | 1993-01-14 | 1996-01-09 | The Regents Of The University Of California | DNA purification by triplex-affinity capture and affinity capture electrophoresis |
| AU2003267785C1 (en) | 2002-09-13 | 2009-12-24 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
| WO2006091798A2 (en) * | 2005-02-22 | 2006-08-31 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus |
| SG187165A1 (en) | 2010-08-20 | 2013-02-28 | Replicor Inc | Oligonucleotide chelate complexes |
| DK2632472T3 (en) * | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| WO2012075114A2 (en) * | 2010-12-01 | 2012-06-07 | Ablitech, Inc. | Nucleic acid-polymer conjugates and uses thereof |
| AU2013262416B2 (en) * | 2012-05-18 | 2017-05-11 | Replicor Inc. | Oligonucleotide chelate complex-polypeptide compositions and methods |
| AR091065A1 (es) * | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| NZ705730A (en) * | 2012-08-30 | 2016-06-24 | Replicor Inc | Methods for the treatment of hepatitis b and hepatitis d infections |
-
2015
- 2015-07-07 AU AU2015286199A patent/AU2015286199B2/en not_active Ceased
- 2015-07-07 PT PT158181487T patent/PT3166615T/pt unknown
- 2015-07-07 PH PH1/2017/500010A patent/PH12017500010B1/en unknown
- 2015-07-07 MX MX2017000053A patent/MX381042B/es unknown
- 2015-07-07 DK DK15818148.7T patent/DK3166615T3/da active
- 2015-07-07 CN CN201580037179.0A patent/CN106659730A/zh active Pending
- 2015-07-07 KR KR1020177003538A patent/KR20170029577A/ko not_active Ceased
- 2015-07-07 BR BR112017000320-1A patent/BR112017000320B1/pt not_active IP Right Cessation
- 2015-07-07 PL PL15818148.7T patent/PL3166615T3/pl unknown
- 2015-07-07 CA CA2954182A patent/CA2954182C/en active Active
- 2015-07-07 HU HUE15818148A patent/HUE064449T2/hu unknown
- 2015-07-07 ES ES15818148T patent/ES2963814T3/es active Active
- 2015-07-07 FI FIEP15818148.7T patent/FI3166615T3/fi active
- 2015-07-07 LT LTEPPCT/CA2015/050626T patent/LT3166615T/lt unknown
- 2015-07-07 MY MYPI2017700005A patent/MY178087A/en unknown
- 2015-07-07 HR HRP20231400TT patent/HRP20231400T1/hr unknown
- 2015-07-07 MD MDA20170014A patent/MD4760C8/ro active IP Right Grant
- 2015-07-07 CN CN202111146395.2A patent/CN113750112A/zh active Pending
- 2015-07-07 SM SM20230380T patent/SMT202300380T1/it unknown
- 2015-07-07 WO PCT/CA2015/050626 patent/WO2016004525A1/en not_active Ceased
- 2015-07-07 KR KR1020237015821A patent/KR102734495B1/ko active Active
- 2015-07-07 HK HK17105180.0A patent/HK1231402A1/zh unknown
- 2015-07-07 JP JP2017501004A patent/JP2017521433A/ja active Pending
- 2015-07-07 EP EP15818148.7A patent/EP3166615B1/en active Active
- 2015-07-07 RS RS20231031A patent/RS64833B1/sr unknown
- 2015-07-07 EA EA201790160A patent/EA036745B1/ru unknown
- 2015-07-07 SG SG11201700073PA patent/SG11201700073PA/en unknown
- 2015-07-07 SI SI201531976T patent/SI3166615T1/sl unknown
- 2015-07-08 US US14/794,129 patent/US9603865B2/en not_active Expired - Fee Related
- 2015-07-13 TW TW104122636A patent/TWI766831B/zh active
-
2016
- 2016-12-20 IL IL249660A patent/IL249660B/en unknown
-
2017
- 2017-01-03 EC ECIEPI201697355A patent/ECSP16097355A/es unknown
- 2017-01-03 CL CL2017000008A patent/CL2017000008A1/es unknown
- 2017-01-03 DO DO2017000002A patent/DOP2017000002A/es unknown
- 2017-01-05 CU CUP2017000001A patent/CU20170001A7/es unknown
-
2020
- 2020-04-20 JP JP2020074639A patent/JP6922030B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3166615T3 (fi) | Kelatoituja fosforotioaattinukleiinihappopolymeerejä käytettäväksi yhdistelmänä HBV-polymeraasin inhibiittorin kanssa hepatiitti B- ja hepatiitti D -virusinfektioiden hoitamiseksi | |
| JP2017521433A5 (enExample) | ||
| Patel et al. | Novel drugs targeting Toll-like receptors for antiviral therapy | |
| TWI620568B (zh) | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 | |
| JP2015528449A5 (enExample) | ||
| JP6668468B2 (ja) | Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法 | |
| CN108026533B (zh) | 拮抗性pdl1适体及其在癌症治疗中的应用 | |
| JP2013522302A5 (enExample) | ||
| JP2016527217A5 (enExample) | ||
| WO2008154482A3 (en) | Sirna compositions and methods of use in treatment of ocular diseases | |
| RU2007101039A (ru) | Иммуностимулирующие олигонуклеотидные мультимеры | |
| WO2007070598A8 (en) | Nucleotide and oligonucleotide prodrugs | |
| JP2016503800A5 (enExample) | ||
| JP2012528867A (ja) | Ｔｌｒ７およびｔｌｒ９の免疫調節オリゴヌクレオチド（ｉｒｏ）アンタゴニストによる自己免疫および炎症性疾患治療の強化 | |
| JP2017518043A5 (enExample) | ||
| JP2015504438A5 (enExample) | ||
| JP2019533682A5 (enExample) | ||
| JP2011515357A5 (enExample) | ||
| US20190224224A1 (en) | Guanosine as an Immune Potentiator Mediated through Toll Receptors | |
| MY209484A (en) | Cpg amphiphiles and uses thereof | |
| JP2011518168A5 (enExample) | ||
| RU2014111179A (ru) | КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ | |
| JP2016520077A5 (enExample) | ||
| Chen et al. | The current status of combination therapy of chronic hepatitis B. | |
| ES2991384T3 (es) | Composición farmacéutica, formulación farmacéutica combinada y kit de formulación combinada para la prevención o el tratamiento de la hepatitis B crónica, que comprende cada uno, como ingrediente activo, un agente antiviral oral y una vacuna terapéutica que incluye un lipopéptido y un adyuvante poli(I:C) |